Zaburzenia erekcji – punkt widzenia kardiologa Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2021
Słowa kluczowe:
kardioseksuologia, inhibitory fosfodiesterazy 5
##plugins.themes.bootstrap3.article.main##
Abstrakt
Schorzenia układu sercowo-naczyniowego są powszechnym zjawiskiem, podobnie jak: otyłość, nadciśnienie tętnicze czy cukrzyca. Wpływają one negatywnie na wszystkie sfery naszego życia, w tym również na nasze życie seksualne. Obecnie najlepiej poznane są wzajemne zależności pomiędzy występowaniem zaburzeń erekcji i chorób układu sercowo-naczyniowego. Zaburzenia erekcji mogą być nie tylko powikłaniem chorób układu sercowo-naczyniowego, lecz także ich wczesnym rewelatorem. Mogą być jednak także działaniem niepożądanym niektórych leków kardiologicznych. Tymi zagadnieniami zajmuje się kardioseksuologia. Być może jednak jeszcze ważniejszym zagadnieniem jest bezpieczeństwo leczenia zaburzeń erekcji u pacjentów kardiologicznych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Mamcarz , A., & Wełnicki , M. (2021). Zaburzenia erekcji – punkt widzenia kardiologa . Medycyna Faktów , 14(1(50), 32-35. https://doi.org/10.24292/01.MF.0121.3
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84: 50-6.
2. Eardley I. The incidence, prevalence and natural history of erectile dysfunction. Sex Med Rev. 2013; 1: 13-6.
3. Braun M, Wassmer G, Klotz T et al. Epidemiology of erectile dysfunction. Results of the Cologne Male Survey. Int J Impot Res. 2000; 12: 305-11.
4. O’Donnell AB, Araujo AB, McKinlay JB. The health of normally aging men: The Massachusetts Male Aging Study (1987-2004). Exp Gerontol. 2004; 39: 975-84.
5. Thompson IM, Tangen CM, Goodman PJ et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005; 294: 2996-3002.
6. Hodges LD, Kirby M, Solanki J et al. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007; 61: 2019-25.
7. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011; 58: 1378-85.
8. Gong B, Ma M, Xie W et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta‑analysis. Int Urol Nephrol. 2017; 49: 1731-40. http://doi.org/10.1007/s11255-017-1644-5.
9. Forgue ST, Patterson BE, Bedding AW et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006; 61(3): 280‐8. http://doi.org/10.1111/j.1365-2125.2005.02553.x.
10. Young JM, Feldman RA, Auerbach SM et al. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. J Androl. 2005; 26(3): 310‐8. http://doi.org/10.2164/jandrol.04126.
11. Washington SL 3rd, Shindel AW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther. 2010; 4: 159‐71. http://doi.org/10.2147/dddt.s9067.
12. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol. 2003; 92(9A): 47M‐57M. http://doi.org/10.1016/s0002-9149(03)00075-4.
13. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol. 2003; 92(9A): 37M‐46M. http://doi.org/10.1016/s0002-9149(03)00074-2.
14. Bocchio M, Pelliccione F, Passaquale G et al. Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. Atherosclerosis. 2008; 196(1): 313‐9. http://doi.org/10.1016/j.atherosclerosis.2006.09.035.
15. Rosano GM, Aversa A, Vitale C et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol. 2005; 47(2): 214‐22. http://doi.org/10.1016/j.eururo.2004.10.002.
16. Manolis AJ, Doumas M, Viigimaa M et al. Hypertension and sexual dysfunction. Choroby Serca i Naczyń. 2007; 4: 65-9.
17. Jackson G, Rosen RC, Kloner RA et al. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med. 2006; 3: 28-3.
2. Eardley I. The incidence, prevalence and natural history of erectile dysfunction. Sex Med Rev. 2013; 1: 13-6.
3. Braun M, Wassmer G, Klotz T et al. Epidemiology of erectile dysfunction. Results of the Cologne Male Survey. Int J Impot Res. 2000; 12: 305-11.
4. O’Donnell AB, Araujo AB, McKinlay JB. The health of normally aging men: The Massachusetts Male Aging Study (1987-2004). Exp Gerontol. 2004; 39: 975-84.
5. Thompson IM, Tangen CM, Goodman PJ et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005; 294: 2996-3002.
6. Hodges LD, Kirby M, Solanki J et al. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007; 61: 2019-25.
7. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011; 58: 1378-85.
8. Gong B, Ma M, Xie W et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta‑analysis. Int Urol Nephrol. 2017; 49: 1731-40. http://doi.org/10.1007/s11255-017-1644-5.
9. Forgue ST, Patterson BE, Bedding AW et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006; 61(3): 280‐8. http://doi.org/10.1111/j.1365-2125.2005.02553.x.
10. Young JM, Feldman RA, Auerbach SM et al. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. J Androl. 2005; 26(3): 310‐8. http://doi.org/10.2164/jandrol.04126.
11. Washington SL 3rd, Shindel AW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther. 2010; 4: 159‐71. http://doi.org/10.2147/dddt.s9067.
12. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol. 2003; 92(9A): 47M‐57M. http://doi.org/10.1016/s0002-9149(03)00075-4.
13. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol. 2003; 92(9A): 37M‐46M. http://doi.org/10.1016/s0002-9149(03)00074-2.
14. Bocchio M, Pelliccione F, Passaquale G et al. Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. Atherosclerosis. 2008; 196(1): 313‐9. http://doi.org/10.1016/j.atherosclerosis.2006.09.035.
15. Rosano GM, Aversa A, Vitale C et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol. 2005; 47(2): 214‐22. http://doi.org/10.1016/j.eururo.2004.10.002.
16. Manolis AJ, Doumas M, Viigimaa M et al. Hypertension and sexual dysfunction. Choroby Serca i Naczyń. 2007; 4: 65-9.
17. Jackson G, Rosen RC, Kloner RA et al. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med. 2006; 3: 28-3.